Meiji Seika Pharma Co. Ltd.
Division of Meiji Holdings Co. Ltd.
www.meiji-seika-pharma.co.jp/english/
Latest From Meiji Seika Pharma Co. Ltd.
No Panic At Newron Over Delayed Schizophrenia Drug Trial
Although the US FDA raised concerns about a rat toxicity trial, causing shares to slide, Italy's Newron believes the trial delay for schizophrenia therapy evenamide is just a blip.
QIDP Roundup: Familiar Names Dominate 2019 Designations
US FDA's Qualified Infectious Disease Product program is growing slowly, but still growing.
Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board
Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer
The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Therapeutic Areas
- Cancer
- Infectious & Viral Diseases
- Neurology, Nervous System
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Parent & Subsidiaries
- Meiji Holdings Co. Ltd.
- Senior Management
- Daikichiro Kobayashi, PhD, Pres.
- Contact Info
-
Meiji Seika Pharma Co. Ltd.
Phone: (81) 3-3272-6511
4-16 Kyobashi 2-chome, Chuo-ku
Tokyo , 104-8002
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice